A Double-Blind Randomised Study of Metronidazole (Flagyl®) 1% Cream in the Treatment of Acne Rosacea

1990 ◽  
Vol 2 (4) ◽  
pp. 242-248 ◽  
Author(s):  
Antoine Bitar ◽  
Jean Bourgouin ◽  
Norman Doré ◽  
Richard Dubuc ◽  
Jean Mario Giroux ◽  
...  
Keyword(s):  
Double Blind ◽  
Randomised Study ◽  
Acne Rosacea

ADMINISTRATION OF MUCOLYTIC SOLUTION BEFORE UPPER ENDOSCOPY – A DOUBLE-BLIND, RANDOMISED STUDY

2018 ◽  
Author(s):  
M Hanousek ◽  
P Falt ◽  
B Pipek ◽  
M Stepan ◽  
P Fojtik ◽  
...  
Keyword(s):  
Upper Endoscopy ◽  
Double Blind ◽  
Randomised Study

Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

1995 ◽  
Vol 74 (02) ◽  
pp. 622-625 ◽  
Author(s):  
H H Brackmann ◽  
R Egbring ◽  
A Ferster ◽  
P Fondu ◽  
J M Girardel ◽  
...  
Keyword(s):  
Factor Xiii ◽  
Bleeding Events ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Randomised Study ◽  
The Mean ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study ◽  
Fxiii Activity ◽  
Observation Period

SummaryThe pharmacokinetics and tolerability of factor XIII (FXIII) from plasma were compared with those of FXIII from placenta in a randomised, double-blind, crossover study involving 13 patients with congenital FXIII deficiency. Both FXIII activity and FXIII antigen were monitored. No difference was seen in the mean half-lives of the two preparations (9.3 days and 9.1 days for plasma and placenta FXIII activity, respectively). Response was similar for both preparations, but was slightly greater for FXIII from plasma.Similar results were found for recovery (65% vs 60%). The area under the data completed by extrapolation was significantly higher for FXIII from plasma. No differences between preparations in terms of efficacy or tolerability were observed. It can be concluded that treatment with FXIII concentrate from plasma is as efficient as with FXIII concentrate from placenta in terms of recovery and half-life. Both preparations were equivalent in terms of safety during the observation period. With the administration of monthly injections of approximately 30 U/kg serious bleeding events were prevented and no other serious adverse events occurred.

PREVENTING VENOUS THROMBOSIS (VT) WITH HEPARIN ALONE OR WITH HEPARIN/DIHYDROERGOTAMINE AFTER ELECTIVE HIP REPLACEMENT, A DOUBLE-BLIND, RANDOMISED, VENOGRAM END-POINT COMPARISON

1987 ◽  
Author(s):  
J F Cade ◽  
K W Mills ◽  
A S Gallus ◽  
W Murphy
Keyword(s):  
Venous Thrombosis ◽  
General Surgery ◽  
Hip Replacement ◽  
Low Dose ◽  
Double Blind ◽  
Randomised Study ◽  
Sodium Heparin ◽  
End Point ◽  
Small Doses

Dihydro-ergotaraine (DHE) appears to be synergistic with small doses of hepari when used to prevent VT after general surgery. However, doubt remains whether DHEhas this effect in patients with elective hip replacement (THR). We have therefore compared the results of VT prophylaxis using sub-cutaneous (sc) low-dose heparinalone or sc heparin plus sc DHE in a double-blind, randomised, study of 126 patientshaving elective THR, 98 at centre (1)and 28 at centre (2).All received 5000 iu sodium heparin, hourly for 7 days, starting 2 hours before surgery at centre (1), or immediately after surgery at centre (2). Patients alsoreceived a separate 0.5 ml (0.5 mg) DHEorplacebo injection each time they receivedheparin. Patients had bilateral ascendingvenography on the 7th postoperativeday, and venograms were read before the treatment code was broken.These results do not support the presence of synergism between heparin and DHE in this situation.

Oral Contrast Media in CT of the Abdomen

1995 ◽  
Vol 36 (4-6) ◽  
pp. 396-398 ◽  
Author(s):  
Maria Lönnemark ◽  
Anders Magnusson
Keyword(s):  
Contrast Media ◽  
Contrast Medium ◽  
Contrast Effect ◽  
Oral Contrast ◽  
Double Blind ◽  
Randomised Study ◽  
Patient Tolerance ◽  
Bowel Opacification ◽  
Oral Contrast Media

In a double blind randomised study 3 different concentrations of iohexol for bowel opacification at CT of the abdomen were compared. Iohexol in a concentration of 4.5 mg I/ml, 6.75 mg I/ml and 9 mg I/ml was used. No significant differences between the 3 preparations of contrast media were found regarding the contrast effect, the distribution or patient tolerance. When using iohexol as a bowel contrast medium at CT the concentration of 4.5 mg I/ml is sufficient for bowel opacification.

Sign in / Sign up

Export Citation Format

Share Document